Evaluation of Needle-free Injection Devices for Intramuscular Vaccination in Horses

Phillips, Jeffrey; Blackford, James T.; Lembcke, Luis M.; Grosenbaugh, Deborah A.; Leard, Timothy

doi:10.1016/j.jevs.2011.06.012

Cited by 17 publications

(19 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The use of this device, for DNA plasmid intramuscular vaccinations, in horses has been previously demonstrated [29]. The vaccination protocol consisted of four biweekly injections on days 0, 14, 28, and 42.…”

Section: Vaccination Protocolmentioning

confidence: 99%

Development of Immunologic Assays to Measure Response in Horses Vaccinated with Xenogeneic Plasmid DNA Encoding Human Tyrosinase

Lembcke¹,

Kania²,

Blackford³

et al. 2012

Journal of Equine Veterinary Science

Self Cite

View full text Add to dashboard Cite

Section: Vaccination Protocolmentioning

confidence: 99%

Development of Immunologic Assays to Measure Response in Horses Vaccinated with Xenogeneic Plasmid DNA Encoding Human Tyrosinase

Lembcke¹,

Kania²,

Blackford³

et al. 2012

Journal of Equine Veterinary Science

Self Cite

View full text Add to dashboard Cite

“…Therefore, it is not possible to distinguish their contribution to the systemic effects. However, the impact of the route of administration on systemic effects is an interesting aspect that warrants investigation in future studies, considering the routes used and, for example, transdermal application methods used for DNA vaccines [ 70 , 71 ].…”

Section: Resultsmentioning

confidence: 99%

Immune response of healthy horses to DNA constructs formulated with a cationic lipid transfection reagent

Schnabel

Steinig

Koy³

et al. 2015

BMC Vet Res

View full text Add to dashboard Cite

BackgroundDeoxyribonucleic acid (DNA) vaccines are used for experimental immunotherapy of equine melanoma. The injection of complexed linear DNA encoding interleukin (IL)-12/IL-18 induced partial tumour remission in a clinical study including 27 grey horses. To date, the detailed mechanism of the anti-tumour effect of this treatment is unknown.ResultsIn the present study, the clinical and cellular responses of 24 healthy horses were monitored over 72 h after simultaneous intradermal and intramuscular application of equine IL-12/IL-18 DNA (complexed with a transfection reagent) or comparative substances (transfection reagent only, nonsense DNA, nonsense DNA depleted of CG).Although the strongest effect was observed in horses treated with expressing DNA, horses in all groups treated with DNA showed systemic responses. In these horses treated with DNA, rectal temperatures were elevated after treatment and serum amyloid A increased. Total leukocyte and neutrophil counts increased, while lymphocyte numbers decreased. The secretion of tumour necrosis factor alpha (TNFα) and interferon gamma (IFNγ) from peripheral mononuclear blood cells ex vivo increased after treatments with DNA, while IL-10 secretion decreased. Horses treated with DNA had significantly higher myeloid cell numbers and chemokine (C-X-C motif) ligand (CXCL)-10 expression in skin samples at the intradermal injection sites compared to horses treated with transfection reagent only, suggesting an inflammatory response to DNA treatment.In horses treated with expressing DNA, however, local CXCL-10 expression was highest and immunohistochemistry revealed more intradermal IL-12-positive cells when compared to the other treatment groups.In contrast to non-grey horses, grey horses showed fewer effects of DNA treatments on blood lymphocyte counts, TNFα secretion and myeloid cell infiltration in the dermis.ConclusionTreatment with complexed linear DNA constructs induced an inflammatory response independent of the coding sequence and of CG motif content. Expressing IL-12/IL-18 DNA locally induces expression of the downstream mediator CXCL-10.The grey horses included appeared to display an attenuated immune response to DNA treatment, although grey horses bearing melanoma responded to this treatment with moderate tumour remission in a preceding study. Whether the different immunological reactivity compared to other horses may contributes to the melanoma susceptibility of grey horses remains to be elucidated.Electronic supplementary materialThe online version of this article (doi:10.1186/s12917-015-0452-3) contains supplementary material, which is available to authorized users.

show abstract

“…The authors and colleagues also documented a decreased prognosis for dogs with advanced stage disease and/or increased time from digit amputation to the start of vaccination. Phillips and co-investigators 95,110 have also recently reported the overexpression of tyrosinase in equine melanoma, determined the safety and optimal use of the needle-free delivery device into the pectoral region with Oncept, and documented antigen-specific humoral responses after vaccination in all horses.…”

Section: Cancer Vaccinesmentioning

confidence: 99%

Immunotherapy in Veterinary Oncology

Bergman¹

2014

Veterinary Clinics of North America: Small Animal Practice

View full text Add to dashboard Cite

Evaluation of Needle-free Injection Devices for Intramuscular Vaccination in Horses

Cited by 17 publications

References 12 publications

Development of Immunologic Assays to Measure Response in Horses Vaccinated with Xenogeneic Plasmid DNA Encoding Human Tyrosinase

Development of Immunologic Assays to Measure Response in Horses Vaccinated with Xenogeneic Plasmid DNA Encoding Human Tyrosinase

Immune response of healthy horses to DNA constructs formulated with a cationic lipid transfection reagent

Immunotherapy in Veterinary Oncology

Contact Info

Product

Resources

About